Clinically Meaningful Gaps Between Clinical Trials and Patient Treatment

In this editorial, we note issues in the psychopharmacological treatment of persons with psychosis, which are usually ignored in regulatory clinical trials and are inadequately addressed in subsequent studies. Virtually all the data to date relate to antipsychotic medications, which have their initiating action at the D2 dopamine receptor.
Source: Schizophrenia Bulletin - Category: Psychiatry Source Type: research